Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387380035> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4387380035 abstract "Abstract Disclosure: K.S. Young: None. G.R. Hancock: None. S. Kregel: None. S.W. Fanning: Advisory Board Member; Self; Olema Oncology. Grant Recipient; Self; Olema Oncology. In the United States, breast cancer is the second leading cause of cancer related deaths among women. Over 70 percent of these breast cancer cases are classified as overexpressing Estrogen Receptor alpha (ERα), denoting that the hormone estrogen fuels the cancer growth. In ER+ breast cancer patients, a distinct tyrosine to serine missense mutation at position 537 (Y537S) leads to hormone- independent ERα activity, causing drug resistance and increased metastatic potential. By favoring the active conformation of ERα, the Y537S mutation reduces binding affinity of small molecule drugs by 5-10 fold. Additionally, this mutation adversely effects the allosteric rearrangement of the receptor that is needed to achieve therapeutic efficacy. Recently, we identified a common structural interaction that distinguishes effective versus ineffective therapeutic antagonists in Y537S breast cancer cells. Based on this relationship, we have developed a new isoquinoline- based antiestrogen (T6I-29-1A) to aid in interpretation of the relationship between ligand binding pose and antagonistic efficacy. Our data suggest that this novel pose effectively antagonizes mutant ERα in breast cancer cells by significantly blunting cell proliferation and downregulating transcriptional activity. Importantly, T6I-29-1A shows potent anti-tumoral activity in ectopic murine xenografts of Y537S ESR1 MCF7 cells, is orally available, and shows a favorable DMPK and ADME profile. Additionally, mice treated with T6I-29-1A exhibited decreased distant metastases compared to hormone-only control. Collectively, these studies point to a distinct relationship between ERα ligand binding pose and novel anti-metastatic activities in drug resistant Y537S ESR1 breast cancer cells. Presentation: Thursday, June 15, 2023" @default.
- W4387380035 created "2023-10-06" @default.
- W4387380035 creator A5037945259 @default.
- W4387380035 creator A5055355934 @default.
- W4387380035 creator A5055553360 @default.
- W4387380035 creator A5064568053 @default.
- W4387380035 date "2023-10-01" @default.
- W4387380035 modified "2023-10-16" @default.
- W4387380035 title "THU546 A Lasofoxifene/Elacestrant Hybrid Antiestrogen Shows Effective Anti-tumoral Activities In Y537S ESR1 Breast Cancer Xenografts" @default.
- W4387380035 doi "https://doi.org/10.1210/jendso/bvad114.2172" @default.
- W4387380035 hasPublicationYear "2023" @default.
- W4387380035 type Work @default.
- W4387380035 citedByCount "0" @default.
- W4387380035 crossrefType "journal-article" @default.
- W4387380035 hasAuthorship W4387380035A5037945259 @default.
- W4387380035 hasAuthorship W4387380035A5055355934 @default.
- W4387380035 hasAuthorship W4387380035A5055553360 @default.
- W4387380035 hasAuthorship W4387380035A5064568053 @default.
- W4387380035 hasBestOaLocation W43873800351 @default.
- W4387380035 hasConcept C121608353 @default.
- W4387380035 hasConcept C126322002 @default.
- W4387380035 hasConcept C134018914 @default.
- W4387380035 hasConcept C143998085 @default.
- W4387380035 hasConcept C172313692 @default.
- W4387380035 hasConcept C2776067312 @default.
- W4387380035 hasConcept C2777176818 @default.
- W4387380035 hasConcept C502942594 @default.
- W4387380035 hasConcept C530470458 @default.
- W4387380035 hasConcept C71924100 @default.
- W4387380035 hasConcept C84606932 @default.
- W4387380035 hasConcept C86803240 @default.
- W4387380035 hasConceptScore W4387380035C121608353 @default.
- W4387380035 hasConceptScore W4387380035C126322002 @default.
- W4387380035 hasConceptScore W4387380035C134018914 @default.
- W4387380035 hasConceptScore W4387380035C143998085 @default.
- W4387380035 hasConceptScore W4387380035C172313692 @default.
- W4387380035 hasConceptScore W4387380035C2776067312 @default.
- W4387380035 hasConceptScore W4387380035C2777176818 @default.
- W4387380035 hasConceptScore W4387380035C502942594 @default.
- W4387380035 hasConceptScore W4387380035C530470458 @default.
- W4387380035 hasConceptScore W4387380035C71924100 @default.
- W4387380035 hasConceptScore W4387380035C84606932 @default.
- W4387380035 hasConceptScore W4387380035C86803240 @default.
- W4387380035 hasIssue "Supplement_1" @default.
- W4387380035 hasLocation W43873800351 @default.
- W4387380035 hasOpenAccess W4387380035 @default.
- W4387380035 hasPrimaryLocation W43873800351 @default.
- W4387380035 hasRelatedWork W1983360066 @default.
- W4387380035 hasRelatedWork W2009983407 @default.
- W4387380035 hasRelatedWork W2025030021 @default.
- W4387380035 hasRelatedWork W2059999025 @default.
- W4387380035 hasRelatedWork W2067533672 @default.
- W4387380035 hasRelatedWork W2113315372 @default.
- W4387380035 hasRelatedWork W2161550802 @default.
- W4387380035 hasRelatedWork W2202843677 @default.
- W4387380035 hasRelatedWork W4252395909 @default.
- W4387380035 hasRelatedWork W181959796 @default.
- W4387380035 hasVolume "7" @default.
- W4387380035 isParatext "false" @default.
- W4387380035 isRetracted "false" @default.
- W4387380035 workType "article" @default.